Avelumab administration at 10mg/kg

DRUG2 trials

Sponsors

Hospices Civils de Lyon, Groupe Oncologie Radiotherapie Tete et Cou

Conditions

Gestational Trophoblastic Neoplasias (GTN)Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Phase 2

Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias

CompletedNCT03135769

Hospices Civils de LyonGestational Trophoblastic Neoplasias (GTN)

Start: 2017-02-21End: 2021-03-17Updated: 2025-12-19

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

RecruitingNCT06640725

Groupe Oncologie Radiotherapie Tete et CouRecurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Start: 2025-01-02End: 2028-12-02Target: 70Updated: 2025-01-15

Related Papers

588 TROPHIMMUN, cohort a: maintained benefit from second-line avelumab after failure to monochemotherapy in low-risk gestational trophoblastic tumor, with a 4 year-follow-up

2024-03-01

Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.

2022-11-1611 citations

273 Avelumab in patients with gestational trophoblastic tumorsresistant to polychemotherapy: efficacy outcomes of cohort B of TROPHIMMUN phase II trial

2021-10-01

Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial

Journal of Clinical Oncology2020-07-2799 citations

Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy: Final outcomes of TROPHIMMUN phase II trial, cohort A.

Journal of Clinical Oncology2020-06-018 citations